XML 92 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions Business Combination Details- Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2017
Dec. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Oct. 03, 2017
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets           $ 8,950
Business Combination, Consideration Transferred $ 11,155          
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 75          
Goodwill Acquired From Business Combination           2,945
Goodwill, Period Increase (Decrease)       $ (42)    
Research and development expenses     $ 9,106 $ 5,018 $ 3,734  
Payments to Outstanding Common Stockholders [Member]            
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Gross 10,420          
Payments to Vested Equity Award Holders [Member]            
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Gross 645          
Payments to Warrant Holders [Member]            
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Gross $ 15          
Share Based Compensation Expense [Member]            
Business Acquisition [Line Items]            
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned           $ 733
Kite Pharma, Inc [Member]            
Business Acquisition [Line Items]            
Business Acquisition, Share Price           $ 180
Intangible Asset - axicabtagene ciloleucel (DLBCL) [Member]            
Business Acquisition [Line Items]            
Finite-Lived Intangible Assets, Period Increase (Decrease)   $ 6,200        
Finite-Lived Intangible Asset, Useful Life   18 years        
Intangible Asset - Daiichi Sankyo [Member]            
Business Acquisition [Line Items]            
Finite-lived Intangible Assets Acquired   $ 91        
Finite-Lived Intangible Asset, Useful Life   14 years        
Cell Design Labs, Inc. [Member]            
Business Acquisition [Line Items]            
Ownership Cell Design Labs, Inc.           12.20%
Asset Acquisition Cash Outflow   $ 150        
Regulatory Milestone-based Payments, Maximum   322     $ 322  
Carrying Value of Equity Interest Owned Prior to Acquisition           $ 30
Research and development expenses   $ 172